Portela-Ortiz JM, Garza-Benavides G, Ocampo-Valencia DBP

Language: Spanish
References: 16
Page: 241-244
PDF size: 187.34 Kb.

ABSTRACT

In December 2019, a coronavirus 2019 (COVID-19) disease outbreak occurred in Wuhan, China, and rapidly spread to other areas worldwide. Although diffuse alveolar damage and acute respiratory failure were the main features, the involvement of other organs needs to be explored. We conducted the review to evaluate the latest evidence on the association between cerebrovascular, cardiovascular and kidney disease, and poor outcome in patients with coronavirus disease 2019 (COVID-19) pneumonia. Cardiovascular, cerebrovascular and kidney disease was associated with increased mortality and borderline increase in severity of COVID-19. Gender, age, hypertension, diabetes, and respiratory comorbidities did not influence the association.

REFERENCES

1. Li J, Li S, Zhao L, Kong D, Guo Z. Management recommendations for patients with chronic kidney disease during the novel coronavirus disease 2019 (COVID-19) epidemic. Chronic Dis Transl Med. 2020;6:119-113.

2. Cheng Y, Luo R, Wang K, Zhang M, Wang Z, Dong L, et al. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int. 2020;97:829-838.

3. Alemzadeh-Ansari M. Coronavirus disease 2019 (COVID-19) and cardiovascular events. Res Cardiovasc Med. 2020;9:1-2.

4. Pérez CA. Looking ahead: the risk of neurologic complications due to COVID-19. Neurol Clin Pract 2020.. 10.1212/CPJ.0000000000000836; doi: 10.1212/cpj.0000000000000836.

5. Saiz FL. Inhibidores del Sistema Renina-Angiotensina como potencial terapia frente al COVID-19. 2020;19:1-4.

6. Klimas J, Olvedy M, Ochodnicka-Mackovicova K, Kruzliak P, Cacanyiova S, et al. Perinatally administered losartan augments renal ACE2 expression but not cardiac or renal Mas receptor in spontaneously hypertensive rats. J Cell Mol Med. 2015;19:1965-1974.

7. Ng JJ, Luo Y, Phua K, Choong AM. Acute kidney injury in hospitalized patients with coronavirus disease 2019 (COVID-19): a meta-analysis. J Infect. 2020;10-13. doi: 10.1016/j.jinf.2020.05.009.

8. Abrishami A, Samavat S, Behnam B, Arab-Ahmadi M, Nafar M, Sanei TM. Clinical course, imaging features, and outcomes of COVID-19 in kidney transplant recipients. Eur Urol. 2020;6-11. doi: 10.1016/j.eururo.2020.04.064.

9. Akhmerov A, Marban E. COVID-19 and the heart. Circ Res. 2020;126:1443-1455. doi: 10.1161/circresaha.120.317055.

10. Pinto D. Coronavirus disease 2019 (COVID-19): coronary artery disease issues. UpToDate 2019. 2020;1-19.

11. Silva BM, Fonseca AF, Souza SV, Araújo AM, Cardoso MG, Brito M, et al. Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. JAMA Netw Open. 2020;3:e208857.

12. Mahmud E, Dauerman H, Welt FG, Messenger JC, Rao SV, Grines C, et al. Management of acute myocardial infarction during the COVID-19 pandemic. J Am Coll Cardiol. 2020; doi: 10.1016/j.jacc.2020.04.039.

13. Flexman AM, Abcejo AS, Avitsian R, De Sloovere V, Highton D, Juul N, et al. Neuroanesthesia practice during the COVID-19 pandemic. J Neurosurg Anesthesiol. 2020;32:202-209. doi: 10.1097/ana.0000000000000691.

14. Li YC, Bai WZ, Hashikawa T. The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients. J Med Virol. 2020;92:552-555.

15. Bourouiba, L. Turbulent gas clouds and respiratory pathogen emissions: potential implications for reducing transmission of COVID-19. JAMA J Am Med Assoc. 2020; E1-E2. doi: 10.1001/jama.2020.4756.

16. Zhang Z, Yao W, Wang Y, Long C, Fu X. Wuhan and Hubei COVID-19 mortality analysis reveals the critical role of timely supply of medical resources. J Infect. 2020;81:147-178. doi: 10.1016/j.jinf.2020.03.018.